# A Study to Test the Safety, Tolerability, and Efficacy of an Antibody, REGN7999, Injected Under the Skin for the Treatment of Iron Overload in Adult Participants With Non-Transfusion Dependent β-thalassemia, Using MRI Scans to Measure Iron Levels in the Body

> **NCT06421636** · PHASE2 · RECRUITING · sponsor: **Regeneron Pharmaceuticals** · enrollment: 95 (estimated)

## Conditions studied

- Non-Transfusion Dependent Beta-Thalassemia (NTDT)

## Interventions

- **DRUG:** REGN7999
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06421636
- **Lead sponsor:** Regeneron Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-09-30
- **Primary completion:** 2028-01-24
- **Final completion:** 2028-01-24
- **Target enrollment:** 95 (ESTIMATED)
- **Last updated:** 2026-03-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06421636

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06421636, "A Study to Test the Safety, Tolerability, and Efficacy of an Antibody, REGN7999, Injected Under the Skin for the Treatment of Iron Overload in Adult Participants With Non-Transfusion Dependent β-thalassemia, Using MRI Scans to Measure Iron Levels in the Body". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06421636. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*